Uncategorized

FDA rejects Sobi’s gout drug over manufacturing issues, sparing Amgen blockbuster

Published

on

Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version